Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 1/20 | 0.60 |
| ▸ | XDH | P47989 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 7/20 | 0.55 |
| ▸ | NPC1 | O15118 | 6/20 | 0.55 |
| ▸ | RAB9A | P51151 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.54 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 7/20 | 0.53 |
| ▸ | MAOB | P27338 | 7/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.53 |
| ▸ | BCL2 | P10415 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29498117 | 1.00 | STS (0.60) | STSXDHMAPTNPC1RAB9A | |
| SCHEMBL12238001 | 0.89 | STS (0.61) | STSXDHMAPTNPC1RAB9A | |
| SCHEMBL15237453 | 0.88 | STS (0.63) | STSXDHMAPTNPC1RAB9A | |
| SCHEMBL16401100 | 0.88 | XDH (0.73) | XDHMAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL12238018 | 0.88 | STS (0.77) | STSXDHMAPTNPC1RAB9A | |
| SCHEMBL16400664 | 0.86 | STS (0.58) | STSXDHMAPTNPC1RAB9A | |
| SCHEMBL17718166 | 0.85 | STS (0.57) | STSXDHMAPTNPC1RAB9A | |
| SCHEMBL17718161 | 0.85 | STS (0.57) | STSXDHMAPTNPC1RAB9A | |
| SCHEMBL17718181 | 0.85 | STS (0.57) | STSXDHMAPTNPC1RAB9A | |
| SCHEMBL13774686 | 0.85 | XDH (0.76) | XDHMAPTNPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2918273-B1 | METHODS AND CELLS FOR IDENTIFYING RIG-I PATHWAY REGULATORS | KINETA INC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-9458492-B2 | Methods and cells for identifying RIG-I pathway regulators | Kineta, Inc. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9408826-B2 | Isoflavone anti-viral compounds | Kineta, Inc. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9408826-B2 | Isoflavone anti-viral compounds | Kineta, Inc. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9408826-B2 | Isoflavone anti-viral compounds | Kineta, Inc. (US) | 2016-08-09 | — | — | US | disclosed |
| WO-2016073947-A1 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Kineta, Inc. (US) | 2016-05-12 | — | — | WO | disclosed |
| US-20160122312-A1 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | Kineta, Inc. | 2016-05-05 | — | — | US | disclosed |
| US-20160122312-A1 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | Kineta, Inc. | 2016-05-05 | — | — | US | disclosed |
| EP-2560652-A2 | ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20130039887-A1 | Methods of Identifying and Using Anti-Viral Compounds | Kineta, Inc. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130039887-A1 | Methods of Identifying and Using Anti-Viral Compounds | Kineta, Inc. (US) | 2013-02-14 | — | — | US | disclosed |
| WO-2012154271-A2 | METHOD AND CELLS FOR IDENTIFYING RIG-I PATHWAY REGULATORS | Kineta, Inc. (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012003030-A9 | METHODS OF IDENTIFYING & USING ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012003030-A2 | METHODS OF IDENTIFYING & USING ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2012-01-05 | — | — | WO | disclosed |
| US-20110262482-A1 | ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110262482-A1 | ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2011133728-A2 | ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133728-A2 | ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262482-A1 | ANTI-VIRAL COMPOUNDS | MAVS, EIF2AK2, IRF3 | STS 4884/4885XDH 2936/4885MAPT 3520/4885 |
| US-20130039887-A1 | Methods of Identifying and Using Anti-Viral Compounds | MAVS, EIF2AK2, DDX5 | STS 4871/4885XDH 1265/4885MAPT 4165/4885 |
| US-20160122312-A1 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | MAVS, EIF2AK2, IRF3 | STS 4837/4885XDH 1629/4885MAPT 3846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.